Key Points
- CEO John Leonard sold 34,146 shares on Jan. 5 at an average of $9.21 for about $314,485, reducing his stake by 3.26% to 1,013,339 shares, per an SEC filing.
- Intellia posted better-than-expected quarterly EPS (‑$0.92 vs. consensus ‑$1.02) with revenue up 51.6% year-over-year to $13.78 million, but remains deeply unprofitable (negative net margin ~774.9%).
- The stock trades near $10 (52-week range $5.90–$28.25) with a market cap of ~$1.17 billion; analysts have a consensus "Hold" rating and an average price target of $18.43 after several recent downgrades and target cuts.
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) EVP Birgit Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares in the company, valued at approximately $907,488.93. The trade was a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
Intellia Therapeutics Trading Up 4.1%
Shares of NASDAQ:NTLA opened at $10.13 on Thursday. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -2.37 and a beta of 2.05. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.25. The business has a fifty day simple moving average of $9.52 and a 200 day simple moving average of $12.68.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, beating analysts' consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business had revenue of $13.78 million for the quarter, compared to the consensus estimate of $14.12 million. During the same period last year, the business earned ($1.34) EPS. The firm's revenue was up 51.6% compared to the same quarter last year. On average, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.
Analyst Upgrades and Downgrades
Several brokerages recently commented on NTLA. Wedbush reduced their target price on Intellia Therapeutics from $9.00 to $7.00 and set a "neutral" rating for the company in a research report on Friday, November 7th. Wall Street Zen lowered shares of Intellia Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, December 27th. Royal Bank Of Canada lowered their target price on shares of Intellia Therapeutics from $14.00 to $9.00 and set a "sector perform" rating on the stock in a research note on Friday, November 7th. HC Wainwright cut their price target on shares of Intellia Therapeutics from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, November 10th. Finally, Wolfe Research reiterated a "peer perform" rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics presently has an average rating of "Hold" and a consensus price target of $18.43.
Read Our Latest Analysis on Intellia Therapeutics
Institutional Trading of Intellia Therapeutics
Large investors have recently added to or reduced their stakes in the company. CWM LLC raised its stake in shares of Intellia Therapeutics by 4.7% in the third quarter. CWM LLC now owns 19,187 shares of the company's stock valued at $331,000 after acquiring an additional 856 shares during the last quarter. Federated Hermes Inc. grew its position in Intellia Therapeutics by 39.7% during the 3rd quarter. Federated Hermes Inc. now owns 3,263 shares of the company's stock worth $56,000 after acquiring an additional 927 shares during the last quarter. Cyndeo Wealth Partners LLC increased its holdings in Intellia Therapeutics by 9.3% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company's stock valued at $202,000 after purchasing an additional 995 shares in the last quarter. Interchange Capital Partners LLC raised its position in Intellia Therapeutics by 9.7% in the 3rd quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company's stock valued at $202,000 after purchasing an additional 1,030 shares during the last quarter. Finally, Benjamin Edwards Inc. boosted its stake in Intellia Therapeutics by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company's stock worth $591,000 after purchasing an additional 1,126 shares in the last quarter. 88.77% of the stock is owned by institutional investors.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
